About Us / Our Research

MELISA Institute was founded to non-invasively investigate pregnancy and very early stages of embryo development looking for ultra-early biomarkers useful to identify diseases during pregnancy (prenatal diagnosis).

In addition, we are interested in developing in utero noninvasive therapeutic options for Trisomy 21 (Down Syndrome) and other genetic or congenital anomalies. We look for preventing or ameliorating associated consequences of this genetic disease.

  MELISA Institute relies on epidemiological research for our commitment with the advance in other important topics such as maternal, embryonic and fetal health determinants, as well as translational medicine initiatives for the wellbeing and health of women in general.